热门资讯> 正文

Biogen Leqembi治疗阿尔茨海默氏症的家庭维持剂量可用

2025-10-07 05:11

Eisai (OTCPK:ESALF) and Biogen (NASDAQ:BIIB) have launched Leqembi IQLIK, a subcutaneous version of their Alzheimer's medication Leqembi (lecanemab) to be given as maintenance doses.
Patients on the treatment must first receive Leqembi as an infusion given every four weeks for 18 months before they can start using the IQLIK autoinjector version, which is taken weekly.
The two companies also unveiled the Leqembi Companion program, which includes access to nurse educators for instructions on how to administer the injections and patient support.
The US FDA approved Leqembi IQLIK in late August.

More on Biogen, Eisai

Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Eisai Co., Ltd. (ESAIY) Discusses On Latest Data On Lemborexant And Novel Orexin Receptor Agonist E2086 At The World Sleep 2025 Transcript
Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Biogen gets complete response letter from FDA for higher dose Spinraza
Biogen to buy Massachusetts-based Alcyone Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。